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CamptothecinCamptothecin (CPT) is a potent broad-spectrum anticancer agent that acts through inhibition of
topoisomerase 1. Clinical development of CPT was unsuccessful due to poor drug solubility, insufﬁcient in
vivo stability of the active form, and toxicity. In order to address these issues, a polymeric nanoparticle
comprised of cyclodextrin-poly(ethylene glycol) copolymer (CDP) conjugated to CPT (CRLX101) has been
developed and Phase 2 clinical studies are ongoing. Camptothecin is conjugated to the polymer in its active
form at 10–12 wt.% loading. CRLX101 self-assembles in solution into nanoparticles with an apparent solubility
increase of N1000-fold as compared to the parent drug camptothecin. Preclinical studies exhibited CRLX101
pharmacokinetics superior to the parent drug. Drug concentration in tumor relative to plasma and other
major organs is consistent with the enhanced permeation and retention (EPR) anticipated from a
nanoparticle. Signiﬁcant anti-tumor activity was observed that is superior when compared to irinotecan
across a broad range of xenograft models. Pharmacokinetic data are consistent with the prolonged half-life
and increased AUC. The CRLX101 preclinical and clinical data conﬁrm that CDP can address not only solubility,
formulation, toxicity, and pharmacokinetic challenges associated with administration of CPT, but more
importantly, can impart unique biological properties, that enhance pharmacodynamics and efﬁcacy of
camptothecin.h International Nanomedicine
on October 3rd–5th, 2010 in
+1 617 494 1544.
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The total market for nanotechnology-enabled drug delivery is
expected to rise to US$ 26 billion by 2012. Besides overcoming
bioavailability hurdles for newly developed drugs, i.e., poor drug
solubility or membrane permeability, nanoparticular drug delivery
can enable reformulation of existing drug products to increase
product lifecycle, and to discourage competition during a drug's
most valuable years. Nanometer-scale carriers may be constructed
from a wide range of organic and inorganic materials such as
emulsions, solid lipid nanoparticles (SLN), nanocapsules, nano-
spheres, micelles, liposomes, dendrimers, quantum dots (QD), and
fullerenes and carbon nanotubes (CNT). These materials are being
used to encapsulate or solubilize chemotherapeutic agents for
improved in vivo drug delivery or to provide unique optical, magnetic
and electrical properties for imaging and therapy. Several functional
nanometer-scale carriers are being evaluated in preclinical and
clinical studies and some have advanced status, including clinically
approved liposome drug formulations and metallic imaging agents.One of the best known examples for reformulated, nanometer-scale
drug delivery is Doxil®. Doxil, approved in the U.S. in 1995, is the poly
(ethylene glycol)-coated, liposome-encapsulated form of doxorubi-
cin, a drug used in cancer chemotherapy. A more recent commercial
product developed by Abraxis Bioscience, LLC, Abraxane®, consists of
an albumin-based reformulation of the anti-cancer drug paclitaxel.
Abraxane was approved in the U.S. in 2005. Examples of lipid
formulations in clinical trials include: CPX-1 (irinotecan-ﬂoxuridine
liposome; Phase 1) and CPX-351 (cytarabine-daunorubicin liposome;
Phase 2), dual drug combinations from Celator Pharmaceuticals, Inc.;
Brakiva™, a liposomal formulation of topotecan from Hana Bios-
ciences; and LEP-ETU (liposomal paclitaxel) from Neopharm, Inc.
Micelle-based drug formulations, i.e., formulations consisting of
hydrophilic-hydrophobic block copolymers that self-assemble in
aqueous solution into micellar particles with a hydrophobic core
and a hydrophilic shell, are in clinical trials as well. NK012 and NK105
are micellar formulations of the camptothecin derivative SN38 and of
paclitaxel, respectively. Both anti-cancer formulations from Nippon
Kayaku Co., Ltd are in Phase 1 trials. Besides physical encapsulation,
drugs have been chemically conjugated to polymers, forming
prodrugs with improved solubility and reduced toxicity. These
prodrugs release the drug based on pH or enzymatic activation at
the desired therapeutic site. Examples are Opaxio™ from Cell
Therapeutics, Inc., a paclitaxel conjugate of poly(glutamic acid).
Inside tumor tissue the drug is released by the enzyme cathepsin B.
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and in combination with carboplatin for the treatment of non-small
cell lung cancer. XMT-1001 from Mersana Therapeutics, Inc. is a
camptothecin prodrug based on the carbohydrate-derived ‘Fleximer’
polyacetal platform, which is currently evaluated in a Phase 1 study.
Other companies are engaged in the development of poly(ethylene
glycol) (PEG)-based prodrugs. NKTR-102 and NKTR-105 are PEG
prodrugs of irinotecan and docetaxel from Nektar Therapeutics,
currently in Phase 2 clinical trial for patients with solid tumor
malignancies, including colorectal, breast, ovarian and cervical
cancers (NKTR-102), and Phase 1 trial in patients with certain types
of solid tumors including hormone-refractory prostate cancer (NKTR-
105). EZN-2208 from Enzon Pharmaceuticals, Inc. is a PEG-prodrug of
SN38. Enzon recently opened its ﬁrst Phase 2 trial for EZN-2208 at
multiple centers throughout the United States for patients diagnosed
with metastatic colon cancer. These few examples clearly demon-
strate the progression of nanotechnology-enabled drug delivery from
basic research curiosities to viable business opportunities.
In contrast to these nanometer-scale carriers, the physical and
chemical properties of polymeric nanoparticles can be designed to
have deﬁned size and surface properties to favor drug deposition and
retention in tumors by extravasation through disorganized, leaky
vasculature commonly found in tumors and inﬂamed tissues,
described as the enhanced permeability and retention (EPR) effect
[1,2]. Furthermore, the design can provide stealth behavior and
physical integrity of polymeric nanoparticles, which can shield drug
molecules from rapid systemic clearance, degradation, and metabo-
lism while in circulation, and prevent broad, systemic drug dissem-
ination and exposure in healthy tissues and organs. Polymeric
nanoparticles can be engineered to incorporate drugs by covalent
conjugation, which can provide control over drug-release kinetics that
could have a signiﬁcant impact on pharmacokinetics and ameaningful
improvement in the drug's pharmacodynamics and efﬁcacy [3,4].
These design features can result in enhanced aqueous solubility,
prolonged plasma half-life, and reduced systemic toxicity of chemo-
therapeutic agents in vivo [3,5]. Finally, the nanoparticle's physical
attributes can also be optimized to facilitate target tissue penetration
and cellular uptake, thereby overcoming drug resistance by circum-
venting surface-pump mediated multi-drug resistance (e.g. P-glyco-
protein-mediated) mechanisms [3].
CRLX101 (formerly IT-101) is a polymeric nanoparticle pharma-
ceutical, developed with the proprietary cyclodextrin polymeric
nanoparticle (CDP) technology [6,7]. It is comprised of camptothecin
(CPT) covalently conjugated to a linear, cyclodextrin-poly(ethylene
glycol) copolymer, which self-assembles into nanoparticles (Fig. 1).
The 20 S-isomer of camptothecin, a natural alkaloid isolated from the
Chinese bush Camptotheca acuminata, was ﬁrst identiﬁed in the
National Cancer Institute (NCI) Anticancer Drug Screen as a promising
cancer drug candidate with signiﬁcant anti-tumor activity [8]. Its
mechanism of action was later discovered to be potent inhibition ofβ-Cyclodextrin (CD)
Camptothecin (CPT)
PEG
Repeat Unit
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Fig. 1. Schematic diagram of CRLX101, a nanopharmceutical comprised of camptothecin
formulated into nanoparticles.topoisomerase 1 (Topo 1), which is an important and validated drug
target for cancer therapy today. Topo 1 remains a highly attractive
drug target because it is essential for basic cellular processes including
DNA replication, recombination, and transcription, which are partic-
ularly up-regulated in rapidly dividing tumor cells [9]. CPT has shown
very high potency and promising anti-cancer activity at low
nanomolar concentrations across a wide range of cancer cell types.
However, development of CPT as a drug molecule was halted because
of its challenging physicochemical and pharmaceutical properties.
Firstly, CPT is poorly water-soluble (approx. 4 μg/mL) and is therefore
not amenable to traditional pharmaceutical formulations. Secondly,
the chemical structure of CPT includes an unstable lactone ring that is
highly susceptible to spontaneous and reversible hydrolysis, which
yields an inactive, but more water-soluble, carboxylate form that
predominates at physiologic pH [10,11]. This inactive carboxylate
form was also found to bind human serum albumin with 200-fold
greater afﬁnity than the active lactone form. In addition, the
carboxylate form lead to bladder toxicity without showing efﬁcacy
when injected into humans [12].
In order to reduce these side effects, a signiﬁcant medicinal
chemistry effort has been devoted to developing CPT analogs. There
are currently two FDA-approved small-molecule CPT analogs in the
market, topotecan (Hycamtin®, GlaxoSmithKline) and irinotecan
(Camptosar®, Pﬁzer) [13]. While their potency is similar to CPT,
both drugs exhibit sub-optimal pharmacokinetics and still have
signiﬁcant dose-limiting toxicities, including bone marrow suppres-
sion and gastrointestinal disorders. A better tolerated CPT molecule
with enhanced efﬁcacy and improved pharmacokinetics, and with a
longer half-life and prolonged bioavailability of the active lactone
form, is a highly attractive cancer drug candidate that could have a
signiﬁcant and favorable clinical impact. Originally designed to
address the challenges associated with CPT, CRLX101 is a nanophar-
maceutical that has proven to augment CPT efﬁcacy by (a) facilitating
target tissue localization and retention, (b) increasing intracellular
CPT deposition, (c) providing a sustained supply of active CPT, (d)
maintaining intracellular CPT concentrations above therapeutic
threshold, and (e) prolonging activity at the CPT target.
2. Results and discussion
2.1. Design of CRLX101
The chemical structure of CRLX101 is comprised of a linear
copolymer backbone incorporating alternating repeat units of
cyclodextrin (CD) and poly(ethylene glycol) (PEG) blocks with
intervening chemical linkers for CPT conjugation. One of the key
design features of the cyclodextrin-poly(ethylene glycol) copolymer
(CDP) is that the CD blocks can form inclusion complexes with
hydrophobic small molecule drugs, such as CPT, through both intra-
and inter-molecular interactions [14]. Interactions between adjacentPolymer Nanoparticles
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Fig. 2. Plasma concentration of CPT (ng/mL) in (A) rat (dose 2.59 mg/kg) and (B) dog
(0.58 mg/kg): CRLX101 shows favorable and consistent pharmacokinetic properties
across species. Filled circles represent total CPT and open circles represent CPT that has
been released from the polymer. The amount of released CPT is b10% in both cases (6.8
and 2.9%, respectively). The fact that the two lines are parallel in each graph indicates
that the drug is being released continuously.
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polymer strands into reproducible nanoparticles with diameters
between 20 and 60 nm. The resulting drug-containing nanoparticles
have neutral surface charge and the PEG blocks impart improved
solubility and stealth properties, which together enable safe systemic
administration, minimize immunogenicity, and help evade phagocyt-
ic uptake by the reticuloendothelial system [15]. As a result, CRLX101
exhibits extended plasma stability with prolonged circulation time,
avoids rapid renal and systemic clearance, and accumulates in target
tissues through the EPR effect.
Two other major design features of CDP as a drug carrier are the
covalent linkage of CPT to the copolymer backbone and the physical
integrity of the resulting self-assembled nanoparticles. To form
CRLX101, CPT is derivatized at the 20-OH position with the natural
amino acid glycine to form an ester linkage for covalent attachment to
the CDP backbone. In vitro chemical characterization studies con-
ﬁrmed that this linker strategy successfully stabilizes the labile
lactone ring of CPT in its closed, active form and prevents premature
CPT inactivation by pH-mediated ring opening upon systemic
administration [6]. In addition, the physical integrity of CRLX101
nanoparticles helps protect CPT from metabolic enzymes and
premature hydrolysis. Consequently, only the active form of CPT is
released in a controlled manner and over a sustained period of time.
Biocompatibility is another important design feature of CDP as a
drug carrier technology. Preclinical animal study data demonstrated
that the CDP polymer, in the absence of conjugated drug, is well
tolerated, eliciting no observable side effects or immune responses,
despite dosing up to 240 mg/kg in mice [6]. In CRLX101, the
intermolecular interactions of CDP polymer strands that catalyze
inclusion complex formation are lost upon CPT release, resulting in
the disassembly of the nanoparticles into individual polymer strands
with hydrodynamic diameters of b10 nm. Such individual polymer
strands are then sufﬁciently small and inert for clearance through the
kidneys. These preclinical ﬁndings are consistent with the clinical
experience of patients tolerating multiple cycles of CRLX101 therapy
without experiencing any unusual or unexpected non-drug related
toxicity caused by the presence of CDP copolymer.
2.2. Pharmacokinetics and Biodistribution Studies with CRLX101
To demonstrate the controlled and sustained CPT release from
CDP, the drug release kinetics and mechanism of CRLX101 were
studied extensively in vitro. Cleavage of the glycine linker was found
to bemediated through both enzymatic and base-catalyzed hydrolysis
of the ester bond, with observed half-lives of 59 h and 41 h in PBS and
human plasma, respectively [16]. Originally published data in reference
[6] indicated a half-life of 1.7 hours in human plasma. However,
subsequent repeat analysis indicated a corrected half-life of 41 hours
in human plasma when the pH was adjusted to pH 7.4. Freshly
reconstituted human plasma had a pH of approx. 9.5 prior to
adjustment. While CPT release kinetics were observed to be relatively
accelerated in plasma compared to PBS, the rate of drug release is slower
than what is typically observed with polymeric prodrugs with an ester
linkage [16]. The in vivo terminal half-life of CRLX101 in plasma after
single-dose injection in rat anddog is similar (24 and28 h, respectively),
suggesting that hydrolysis of the glycine linker is not rate-limiting
(Fig. 2). The observed slowand sustainedCPT release fromCRLX101also
illustrates the physical shielding effects of CDP, which form intact
nanoparticles, and thereby protect the CPT payload and minimize the
enzymatic and chemical hydrolytic degradation.
Drug concentrations in plasma and tumor were further assessed in
tumor-bearing mice (Daudi B-cell lymphoma xenograft, single-dose
pharmacokinetic study), comparing CRLX101 with the approved Topo
1 inhibitor irinotecan, a small-molecule prodrug of the active
metabolite SN-38 [17]. In this experiment, drug levels were assessed
in plasma samples and tumor biopsies harvested after administrationof irinotecan and CRLX101 at their respective maximum tolerated
dose (MTD). The results showed that, at 24 and 48 h post-
administration, plasma and tumor concentrations of both CRLX101
and released CPT were more than four orders of magnitude higher
than those of irinotecan and more than two orders of magnitude
higher than those of SN-38 (Fig. 3). These ﬁndings correlate very well
with the signiﬁcantly enhanced efﬁcacy observed with CRLX101
compared to irinotecan in several xenograft tumor models. Most
remarkably, the enhanced efﬁcacy and increased tumor drug
concentrations were correlated with increased inhibition of Topo 1
enzymatic activity in two of the tumor models (Daudi and Karpas
299) at 48 h post-administration [17].
Key goals for the design of CRLX101 are increased efﬁcacy and
improved systemic tolerability through enhanced drug deposition in
tumor tissue. Therefore, the biodistribution of CRLX101 was evaluated
in xenograft tumor-bearing mice (LS174t colorectal xenograft, single-
dosepharmacokinetic study) by assessing localizeddrug concentrations
in target tissues (Table 1). In this study, tumors and other organs were
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Fig. 3. (A) Plasma (ng/mL) and (B) tumor (ng/g) concentrations of conjugated CPT
(ﬁlled circles), released CPT (open circles), irinotecan (ﬁlled triangles), and its active
metabolite SN-38 (open triangles). Drugs were given as single dose at the respective
MTD (CRLX101 10 mg/kg and irinotecan 100 mg/kg). CRLX101 levels are quite
sustained in both plasma and tumor over 48 h, whereas irinotecan and SN-38 levels
decline rapidly, illustrating superior pharmacokinetic proﬁle and longer terminal half-
life of CRLX101 compared to irinotecan and SN-38. (Adapted from reference [17]).
Table 2
CRLX101 showed superior anti-tumor activity over commercial front-line drugs in
multiple xenograft models.
(Data from references [14,17,19]).
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and assessed for localized drug concentrations. Remarkably, in tumor
tissues harvested from animals treated with CRLX101 at its MTD,
signiﬁcantly higher intratumoral concentrations of released CPT wereTable 1
Biodistribution of CRLX101 in nude mice bearing subcutaneous, human LS174T
colorectal cancer xenografts. Plasma and tissue collection at 24 and 48 h after single-
dose administration at respective MTD (3 mg/kg intraperitoneally for CPT and 24 mg/
kg CPT equivalent dose intravenously for CRLX101).
(Data from reference [18]).
Tissue\
time point
Level of released, active CPT
(ng/mL or ng/g)
CRLX101 CPT
24 h 48 h 24 h 48 h
Plasma 72±9 3±3 0±0 0±0
Tumor 183±115 55±22 1±0 0±0
Liver 241±132 121±57 106±40 108±74
Spleen 45±42 13±17 49±15 0±0
Lung 57±43 11±9 8±15 0±0
Heart 23±21 5±5 0±0 14±0measured at 24 and 48 h post-administration, compared to tumor CPT
concentrations found in animals treated with CPT at its MTD [18].
Furthermore, the level of released CPT in tumor relative to plasma
gradually increased from approximately a 2.5:1 tumor-to-plasma ratio
at 24 h to 21:1 at 48 h post-administration. These observations are in
sharp contrastwith thedata observed in animals administeredwith free
CPT. In summary, ﬁndings from CRLX101 biodistribution studies
provide substantive evidence that CDP nanopharmaceuticals can
increase the efﬁcacy of the activemolecule by enhancing and sustaining
higher localized drug concentrations in target tissues.
2.3. Efﬁcacy and tolerability studies with CRLX101
A comprehensive evaluation of CRLX101 anti-tumor activity has
been completed in multiple subcutaneous human cancer models,
including LS174T and HT29 colorectal cancer, A2780 and SK-OV 3
ovarian cancer, H1299 non small-cell lung cancer, H69 small-cell lung
cancer, Panc-1 pancreatic cancer, MDA-MB-231 breast cancer, along
with four disseminated xenograft models, including Daudi, Karpas
299, and L540 lymphomas (Table 2). In every case, a single treatment
cycle of three weekly doses of CRLX101 resulted in signiﬁcant anti-
tumor activity that was superior to commercial comparators including
irinotecan and topotecan (Figs. 4 and 5). Most notably, complete
tumor regression was observed in all animals bearing H1299 and
A2780 tumors, and in the majority of animals with disseminated
Daudi, and Karpas 299 lymphoma tumors.
CRLX101 was found to be highly effective in tumor models that
respond poorly to treatment with irinotecan (MDA-MB-231, Panc-1,
and HT29), suggesting the potential ability of CRLX101 to overcome
the lack of drug response in these models. Overall, these ﬁndings
provide compelling support that CDP as a nanopharmaceutical
technology has (a) successfully overcome formulation, toxicity, and
pharmacokinetic challenges of CPT, (b) maintained CPT in its active
form resulting in potent anti-tumor activity, (c) increased intracellu-
lar CPT concentrations, (d) enhanced tumor drug localization and
retention, and (e) produced a sustained therapeutic effect with
superior efﬁcacy over approved Topo 1 inhibitors.
2.4. Combination therapy with CRLX101
The increased therapeutic window of CRLX101 might offer the
opportunity to combine this agent with other chemotherapeutic agents
for synergistic activity. Studies were therefore conductedwith CRLX101
in combination with the highly efﬁcacious chemotherapeutic agentsXenograft
model
Tumor
type
Comparator
drug
CRLX101 vs comparator
median survival (MS)
fold improvement
Study
duration
(days)
H1299 NSCLC Topotecan N6.1 90
H69 SCLC Irinotecan N2.0 95
Panc-1 Pancreatic Irinotecan N3.3 91
MDA-MB-231 Breast Irinotecan 3.5 70
A2780 Ovarian Topotecan N6.3 60
SK-OV-3 Ovarian Topotecan 5.9 60
LS174t Colorectal Irinotecan 4.5 71
HT-29 Colorectal Irinotecan N2.4 60
DAUDI (sc) Lymphoma Irinotecan N5.0 126
DAUDI (dissem) Lymphoma Irinotecan N4.8 126
Karpas 299 (sc) Lymphoma Irinotecan 3.0 126
Karpas 299
(dissem)
Lymphoma Irinotecan 1.7 126
L540 Hodgkin (sc) Lymphoma Irinotecan N14 126
Median Survival
Fold Improvement =
CRLX101 MSVehicle MS daysð Þ
Comparator MSVehicle MS daysð Þ :
Days from Start of Therapy
CRLX101
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Fig. 4. Efﬁcacy study of CRLX101 compared to irinotecan using a disseminated Daudi B-cell lymphoma xenograft in mice. Above: bioluminescence study using Daudi B-cell line
expressing luciferase activity. Weekly dosing ×3 at 100 mg/kg (irinotecan), 5 mg/kg (CRLX101, triangles), and 10 mg/kg (CRLX101, diamonds). Below: corresponding survival
graphs. CRLX101 achieved 55.6% complete tumor response at Day 125 post-treatment at the 10 mg/kg dose, while no complete tumor responses were observed in irinotecan-treated
mice. (Adapted from reference [17]).
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activity of such drug combinations was tested in xenograft tumor
mouse models, including human A2780 and SK-OV-3 ovarian
carcinoma [20]. In these studies, all CRLX101 drug combinations
tested were found to exhibit greater than additive efﬁcacy, compared
to the single-agent activity observed with each of the individual
chemotherapeutic agents. Furthermore, in the case of cisplatin,
paclitaxel, and gemcitabine, the observed enhanced efﬁcacy from
combination therapy was achieved without additive toxicity. A key
clinical implication from these ﬁndings is that CRLX101 can be
developed as a highly versatile chemotherapeutic agent that has
signiﬁcant monotherapy activity, with the potential for combination
with multiple widely-used oncology agents.
2.5. Clinical Phase 1 study with CRLX101
The preclinical studies of CRLX101 have conﬁrmed that the CDP
technology provides superior pharmacokinetics, improved tolerabil-
ity, enhanced pharmacodynamics, and increased efﬁcacy to CPT.
Considering the original promise of CPT as an anti-tumor agent andthe favorable pharmaceutical proﬁle of its design and conﬁguration,
CRLX101 is a promising oncology agent, and clinical development was
initiated. The primary objectives of the Phase 1 study were to
determine the safety, pharmacokinetics, dose-limiting toxicities,
maximum tolerated dose (MTD), as well as the recommended dose
and dosing schedule. Secondary objectives of the study included the
assessment of potential biomarkers, an estimation of clinical activity
by RECIST, and an estimation of progression-free survival in patients
receiving six ormoremonthly cycles of CRLX101monotherapy. In this
study, CRLX101 was administered intravenously to patients with
advanced solid tumors and conﬁrmed progressive disease that had
relapsed or was refractory to standard therapy. The Phase 1 study of
CRLX has been successfully completed, and detailed data will be
published elsewhere. A randomized Phase 2 study is currently being
initiated.
3. Conclusions
The application of polymeric nanoparticles addressing formulation
and pharmacokinetic challenges has long been a hot topic in drug
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Fig. 5. Efﬁcacy study of CRLX101 compared to topotecan using xenograft tumor-bearing
mice (A2780 ovarian xenograft). (A) Tumor growth delay and (B) survival graphs
showing vehicle (circles), CRLX101 (diamonds, 12 mg/kg, weekly ×3), and topotecan
(triangles, 12 mg/kg, every 4 days ×3). Arrows indicate the respective treatment days.
CRLX101 shows superior survival compared to topotecan, both treated at optimized
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Fig. 6. (A) Tumor growth delay and (B) survival graphs in the A2780 ovarian xenograft
model showing vehicle (circles), monotherapy efﬁcacy of CRLX101 (ﬁlled squares,
5 mg/kg), cisplatin (ﬁlled diamonds, 7 mg/kg), and carboplatin (ﬁlled triangles,
100 mg/kg), and combination therapy efﬁcacy of CRLX101+cisplatin (open diamonds,
5+7 mg/kg) and CRLX101+carboplatin (open triangles, 5+100 mg/kg). Both
combination therapies are more efﬁcacious than the respective monotherapies, with
the combination CRLX101+cisplatin providing 100% survival up to day 70 after
treatment, suggesting a mechanistic synergism between platinum drugs, which cause
DNA damage, and CRLX101, which affects DNA repair. A sub-optimal dose of CRLX101
was used in this study because the MTD of CRLX101 alone causes complete tumor
regression, as shown in Fig. 5. (Adapted from reference [20]).
54 S. Svenson et al. / Journal of Controlled Release 153 (2011) 49–55delivery research and development. Advances in polymer chemistry
and a better understanding of tumor microenvironment biology have
supported the progress of nanopharmaceuticals as a new class of
therapeutic agents. While other nanometer-scale drug carrier tech-
nologies and approaches have demonstrated an ability to overcome
some of the formulation and pharmacokinetic hurdles, development
of CRLX101 as a ﬁrst-in-class nanopharmaceutical has established that
cyclodextrin polymeric nanoparticle technology is a highly versatile
platform technology that confers signiﬁcant biological advantages to
active pharmaceutical ingredients, including target-tissue localiza-
tion, enhanced cellular uptake, and slow drug release kinetics, all
resulting in sustained therapeutic drug concentrations in target cells.
Together, these biological properties provide a strong potential to
translate therapy into signiﬁcant impact on clinical outcome.References
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